Steven E. Canfield

Overview JoinDr Moez Aziz (Baylor College of Medicine, US), Dr Steven Canfield(University of Texas McGovern Medical School, US), Michele R. Cole (Sumitomo Pharma America, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) for an insightful webinar on the cardiotoxicity of first-line therapies for advanced prostate cancer.

Keywords Cardiotoxicity Heart failure Myocarditis Vascular toxicity Hypertension Arrhythmias Docetaxel Abiraterone acetate Darolutamide Olaparib What does this study add? Androgen deprivation therapy (ADT) plus docetaxel (DTX) plus darolutamide offers less cardiotoxicity than ADT + DTX plus abiraterone acetate with prednisone (AA + P) for metastatic hormone-sensitive prostate cancer due to less mineralocorticoid excess.

The importance of providing clinical guidance that is based on the best available knowledge cannot be overstated; this task is one of the most crucial mandates of any medical organisation. The challenge has always been the changing nature of our understanding not only of medical treatments, of course, but also of what defines the best available knowledge.